Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
Oprah Winfrey reveals taking GLP-1 weight-loss drug made her realize what she got wrong about ‘thin people’
The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That changed after a special on weight loss with experts and clinicians that she taped in July 2023. The panel discussion left her with her “biggest aha moment” about the medication.
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,
GLP-1 weight loss drugs linked to a wide range of health benefits and risks: study
A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs.
28 benefits, 16 risks: How popular GLP-1 weight loss drugs reshape human health – for better and worse
A new study reveals that popular diabetes and weight loss medications like Ozempic and Wegovy may offer unexpected health benefits, from reducing addiction risk to protecting against Alzheimer’s disease.
Popular Weight Loss Drugs Could Affect Your Behavior: Scientists Conduct Genetic Investigation
A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), widely used medications for managing type 2 diabetes and obesity,
Not Just For Weight Loss: GLP-1 Drugs May Affect Addiction And Dementia Risk
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
Popular GLP-1 Drugs Are Shaping Health Beyond Weight Loss & Diabetes
Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions
GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits,
Weight-Loss Drugs Like Ozempic Linked To Lower Risk Of 42 Conditions
Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.
The Health Risks and Benefits of Weight-Loss Drugs
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,
Medical News Today
3d
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
3d
on MSN
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
6d
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Los Angeles wildfire updates
Confirmed to lead Pentagon
Manson won't face charges
‘Lassie' actor dies at 91
Barred from entering DC
Giant iceberg on the move
Bans some tattoos, clothes
Extradition challenge denied
Alleged assault cover-up suit
Trump ends security detail
Proposes ending FEMA
Consumer sentiment falls
Woman arrested in shooting
World's most polluted cities
Crack down on fake reviews
Suspends all trips to Yemen
Ex-Nebraska RB Jones dies
Fined over smartwatch burns
Woman indicted in car crash
Proposed ban withdrawn
Millions missed school
Unveils Operator agent
Hamas to release 4 hostages
China's trade status bill
Reviews charter schools
Newark mayor criticizes raid
US home sales fell
Wallen announces tour
Pandas make public debut
Target ending its DEI goals
Debuts AI assistant
Jabrill Peppers testifies
Related topics
Novo Nordisk
Ozempic
Wegovy
Feedback